The Claim
In adults with type 1 diabetes, insulin glargine U300 reduces 24-hour free fatty acid concentrations by approximately 19% (0.81 mmol/L, 90% CI 0.73–0.89) and glycerol by 22% (0.78 mmol/L, 90% CI 0.65–0.94) compared to insulin glargine U100 under euglycemic clamp conditions.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 1 diabetes, insulin glargine U300 lowers free fatty acid and glycerol levels in the blood more than insulin glargine U100 when blood glucose is held steady.
See the scientific wording
In adults with type 1 diabetes, insulin glargine U300 reduces 24-hour free fatty acid concentrations by approximately 19% (0.81 mmol/L, 90% CI 0.73–0.89) and glycerol by 22% (0.78 mmol/L, 90% CI 0.65–0.94) compared to insulin glargine U100, indicating greater suppression of lipolysis under euglycemic clamp conditions.
A longer-lasting form of insulin keeps blood insulin levels steady for more hours, which tells the pancreas to release less glucagon. With less glucagon and more insulin, fat cells stop breaking down stored fat, so fewer free fatty acids and glycerol enter the bloodstream.
What the research says
1 studyIn people with type 1 diabetes, a longer-lasting form of insulin called glargine U300 does a better job of slowing down fat breakdown than the older version, glargine U100, leading to lower levels of fat-related chemicals in the blood — without affecting blood sugar levels.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.